US Patent 11591595 Compositions for modulating Tau expression
Patent 11591595 was granted and assigned to Biogen on February, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Apr, 2023
Golden AI
Infobox
Edits on 30 Mar, 2023
Golden AI
Edits on 23 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 20 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115915950
Date of Patent
February 28, 2023
0Patent Application Number
169867700
Date Filed
August 6, 2020
0Patent Citations
Patent Primary Examiner
Edits on 1 Mar, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+238 characters)
US Patent 11591595 Compositions for modulating Tau expression
Article
Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115915950
Date of Patent
February 28, 2023
0Patent Application Number
169867700
Date Filed
August 6, 2020
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11591595 Compositions for modulating Tau expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.